The situation is further complicated by the fact that based on the current drug treatment (e.g., lipid-lowering, blood-pressure-regulating medications, SGLT2 inhibitors, GLP1 analogs, among others) and prevention procedures recommended by KDIGO 1a evidence, the risk of cardiovascular death in patients with G4-stage CKD is expected to decline. Here, SLC5A2 is linked to chronic kidney disease.